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Abstract
The clinical significance ofMycobacterium kansasii respiratory isolates is uncertain. The
aims of this study were to determine the clinical relevance ofM. kansasii isolates and to
identify the clinical features and outcomes ofM. kansasii lung disease. We reviewed the
medical records of 104 patients from whom at least one respiratoryM. kansasii isolate was
obtained from January 2003 to July 2014 at Samsung Medical Center, South Korea. Of
these 104 patients, 54 (52%) met the diagnostic criteria for nontuberculous mycobacterial
lung disease; among them, 41 (76%) patients received antibiotic treatment for a median
time of 15.0 months (interquartile range [IQR], 7.0–18.0 months). The remaining 13 (24%)
without overt disease progression were observed for a median period of 24.0 months (IQR,
5.0–34.5 months). Patients withM. kansasii lung disease exhibited various radiographic
findings of lung disease, including the fibrocavitary form (n = 24, 44%), the nodular bronch-
iectatic form (n = 17, 32%), and an unclassifiable form (n = 13, 24%). The fibrocavitary form
was more common in patients who received treatment (n = 23, 56%), while the nodular
bronchiectatic form was more common in patients withM. kansasii lung disease who did not
receive treatment (n = 9, 70%). None of the patients with a single sputum isolate (n = 18)
developedM. kansasii disease over a median follow-up period of 12.0 months (IQR, 4.0–
26.5 months). In total, 52% of all patients withM. kansasii respiratory isolates exhibited clini-
cally significant disease. Moreover, patients withM. kansasii lung disease displayed diverse
radiographic findings in addition to the fibrocavitary form. The nodular bronchiectatic form
was more common in patients withM. kansasii lung disease with an indolent clinical course.
Thus, since the clinical significance of a singleM. kansasii respiratory isolate is not definite,
strict adherence to recommended diagnostic criteria is advised.
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Introduction
Nontuberculous mycobacteria (NTM) are environmental organisms that can be isolated from
water, soil, plants, animals, and dust [1, 2]. NTM are increasingly recognized as pathogenic to
humans, with pulmonary disease being the most common manifestation of NTM infection [3,
4]. UnlikeMycobacterium tuberculosis, NTM derived from respiratory isolates must be exam-
ined to distinguish colonizer or contaminant from a true pathogen responsible for lung disease.
Therefore, the American Thoracic Society (ATS) and the Infectious Diseases Society of Amer-
ica (IDSA) have issued diagnostic criteria for NTM lung disease [5].
Mycobacterium kansasii is a slow-growing NTM and the second most common cause of
NTM lung disease in some European countries including the United Kingdom, Slovakia, and
Poland [6]. Traditionally,M. kansasii has been considered the most virulent NTM species and
the presence of a singleM. kansasii isolate in a sputum sample has been believed to be clinically
significant by many experts [7, 8]. However, the degree of correlation betweenM. kansasii iso-
lation respiratory samples and true lung disease has not been definitely established. Previous
reports from the United States and the United Kingdom found that more than 70% of all
patients with a respiratory isolate ofM. kansasii had clinically relevant disease [9–11]. How-
ever, studies from Asian countries found that only 17% of allM. kansasii isolates from respira-
tory samples were clinically relevant according to the ATS/IDSA diagnostic criteria [12].
The typically recognized clinical presentation of NTM lung disease, includingM. kansasii
lung disease, is an apical fibrocavitary form that is nearly identical to pulmonary tuberculosis.
This type of disease usually develops in older males with a history of lung disease, such as previ-
ous pulmonary tuberculosis [5]. NTM lung disease can also present with nodular infiltrates,
which frequently involve the right middle lobe and the lingular segment of the left upper lobe
(nodular bronchiectatic form). This form of disease occurs predominantly in postmenopausal,
non-smoking females and is also common inMycobacterium avium complex (MAC) lung dis-
ease [13–15]. However, the nodular bronchiectatic form ofM. kansasii lung disease has not
been well described in the literature.
In South Korea, the frequency of NTM isolation and the number of patients diagnosed with
NTM lung disease are both steadily increasing [16, 17].M. kansasii has been shown to repre-
sent only 1–2% of all NTM isolates and pathogens in NTM lung disease in South Korea [16–
18]. In this study, we reviewed the medical records of all patients from whomM. kansasii was
isolated from respiratory specimens taken during a 12-year period at our institution. The aims
of this study were to determine the clinical relevance ofM. kansasii isolates and to identify the
clinical features and outcomes ofM. kansasii lung disease.
Patients and Methods
Using our mycobacterial laboratory database, all patients for whom an isolate ofM. kansasii
was present in at least one of two or more respiratory specimens taken at Samsung Medical
Center (a 1,961-bed referral hospital in Seoul, South Korea) between January 2003 and July
2014 were identified. This retrospective observational study was approved by the Institutional
Review Board of Samsung Medical Center (IRB No. 2014-10-093) and full permission was
granted to review and publish information obtained from patient records. Informed consent
was waived for the use of patient medical data because patient information was anonymized
and de-identified prior to analysis.
During the study period, NTM species were identified using polymerase chain reaction
(PCR)-restriction fragment length polymorphism analysis or a PCR-reverse blot hybridization
assay of the mycobacterial rpoB gene [19, 20]. Antimicrobial susceptibility testing was per-
formed at the Korean Institute of Tuberculosis. The minimum inhibitory concentration (MIC)
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of rifampin and clarithromycin was evaluated via the broth microdilution method and inter-
preted according to the National Committee for Clinical Laboratory Standard guidelines [21],
which had been implemented since January 2009 in Korea.
For each patient, clinical, microbiological and radiographic data were evaluated. Chest radi-
ography scans and chest high-resolution computed tomography (HRCT) images were available
for all patients and these images were reviewed by two of the authors (S. M. Moon and H. Y.
Park) with respect to the presence or absence of nodules, consolidation, cavitary lesions, and
bronchiectasis [22]. Patients were then diagnosed withM. kansasii lung disease if they met the
2007 ATS/IDSA diagnostic criteria [5]. After evaluating the clinical significance theM. kansasii
isolates, the chest radiography and HRCT findings were classified as showing either the fibro-
cavitary form or the nodular bronchiectatic form. If the disease did not belong to either of
these categories, it was deemed unclassifiable [23, 24].
In patients with extensive lesions and respiratory symptoms, physicians started treatment
forM. kansasii lung disease immediately. However, if patients had mild symptoms without
clear progression, treatment was not initiated and they were instead followed regularly and
sputum cultures were collected. During the follow-up period, patients who showed disease pro-
gression began treatment. At that time, the goal of treatment was maintenance of negative spu-
tum conversion over 12 months with improvement in symptoms and performed images [15,
23]. When the patients were treated forM. kansasii lung disease, sputum conversion was
defined as three consecutive negative cultures, with the time of conversion defined as the date
of the first negative culture [15, 23]. The patients who completed treatment were followed regu-
larly including repeated sputum acid-fast bacilli (AFB) culture for investigation of recurrence.
Microbiologic recurrence was defined as two consecutive positive cultures after sputum con-
version. Treatment outcomes were evaluated on December 31, 2014. At this point, if the
intended treatment was finished, patient were categorized as having completed treatment and
if patients were receiving treatment, they were categorized in the ongoing treatment group. If
antibiotics were stopped with or without follow-up, patients were categorized as ‘discontinued’
or ‘lost to follow-up,’ respectively. Transfer of the patient to another hospital was described as
‘transfer’; if the patient died in our hospital because of the progression ofM. kansasii lung dis-
ease, they were classified as ‘death during treatment’. In addition, for each patient, the test
result of anti-human immunodeficiency virus (HIV) antibody screening was reviewed
retrospectively.
All data are presented as medians and interquartile ranges (IQRs) for continuous variables
and as numbers (percentages) for categorical variables. Data were compared using the Mann-
Whitney U test for continuous variables and Pearson’s χ2 test or Fisher’s exact test for categori-
cal variables. All statistical analyses were performed using PASW Statistics 21 (SPSS Inc., Chi-
cago, IL, USA).
Results
Baseline Characteristics
From January 2003 to July 2014, 104 patients were identified withM. kansasii-positive cultures
from 230 respiratory specimens. These specimens consisted of 217 sputum samples, 12 bron-
chial washing fluid samples and 1 lung tissue aspiration sample. Out of 104 patients, 102
patients had three or more available specimens. The patient baseline characteristics are detailed
in Table 1. Of the 104 patients withM. kansasii respiratory isolates, 54 (52%) met the ATS/
IDSA diagnostic criteria for NTM lung disease and 50 (48%) did not meet the 2007 ATS/IDSA
criteria forM. kansasii lung disease. However, there was no significant difference in baseline
characteristics between two groups. In total, 71 males (68%) and 33 females (32%) were
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included in this study, with a median age of 59 years (IQR, 45–67 years). The median body
mass index was 20.6 kg/m2 (IQR, 18.8–22.9 kg/m2) and 48 (46%) patients were nonsmokers.
The most frequent pre-existing pulmonary disease was a prior history of pulmonary tuberculo-
sis (n = 39, 38%), followed by bronchiectasis (n = 37, 37%) and chronic obstructive pulmonary
disease (n = 17, 16%). All patients were immunocompetent except one patient with myelodys-
plastic syndrome; Anti-HIV antibody test screening was performed in 85 (82%) of 104 patients,
and none of the untested patients had risk factors for HIV infection.
All 104 patients withM. kansasii isolates were followed for a median of 21.7 months (IQR,
9.0–33.2 months). AfterM. kansasii was isolated, a median of 7.0 (IQR 3.0–11.0) sputum cul-
tures were obtained during follow-up period.
Comparison of Clinical Manifestations and Radiographic Findings
Between Patients withM. kansasii Lung DiseaseWho Received
Antibiotic Treatment Versus ThoseWho Did Not
Among 54 patients who met the ATS/IDSA diagnostic criteria for NTM lung disease, 41 (76%)
received antibiotic treatment and the median duration from diagnosis to initiation of treatment
was 1.7 months (0.3–3.8 months). The remaining13 (24%) patients with mild symptoms
underwent regular follow-up without antibiotic treatment for a median time of 26.5 months
(IQR, 8.8–35.3 months) and a median of 8.0 (IQR 3.0–11.5) sputum cultures were obtained
during follow-up. Based on the chest radiography and HRCT findings in all 54 patients, 24
(44%) patients manifested the fibrocavitary form, 17 (32%) had the nodular bronchiectatic
form, and 13 (24%) exhibited an unclassifiable form ofM. kansasii lung disease. The diverse
radiographic findings are shown in Fig 1.
We compared clinical and radiographic manifestations between patients withM. kansasii
lung disease who received antibiotic treatment versus those who did not. As shown in Table 2,
many of the clinical manifestations, including symptoms and the number of patients with a
Table 1. Baseline characteristics of the 104 patients withM. kansasii-positive cultures from respiratory specimens.
Characteristics Total (n = 104) Met ATS criteria (n = 54) Did not meet ATS criteria (n = 50) P value
Males, n (%) 71 (68) 39 (72) 32 (64) 0.368
Age, years 59 (45–67) 62 (45–66) 57 (42–67) 0.427
Body mass index, kg/m2 20.6 (18.8–22.9) 20.7 (18.7–22.8) 20.3 (18.9–23.0) 0.735
Current or ex-smoker, n (%) 60 (58) 35 (65) 25 (50) 0.127
Pre-existing pulmonary disease, n (%)
Prior pulmonary tuberculosis 39 (38) 16 (30) 23 (46) 0.085
Bronchiectasis 38 (37) 15 (28) 23 (46) 0.054
Chronic obstructive pulmonary disease 17 (16) 11 (20) 6 (12) 0.249
Interstitial lung disease 6 (6) 4 (7) 2 (4) 0.680
History of previous lung surgery 8 (8) 3 (6) 5 (10) 0.477
Comorbidity, n (%)
Malignancy 11 (11) 5 (9) 6 (12) 0.650
Diabetes mellitus 11 (11) 7 (13) 4 (8) 0.411
Immunocompromised disease* 1 (1) 1 (2) 0 (0) 1.000
All data are presented as numbers (%) or as medians and interquartile ranges.
ATS: 2007 American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) diagnostic criteria for nontuberculous mycobacterial
lung disease.
*This patient had myelodysplastic syndrome.
doi:10.1371/journal.pone.0139621.t001
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positive AFB smear, did not differ between the two groups. However, patients withM. kansasii
lung disease who received antibiotic treatment were more likely to have the fibrocavitary form
of disease than those who did not receive antibiotic treatment (56% vs. 8%, p = 0.002), while
the nodular bronchiectatic form was observed more often in patients withM. kansasii lung dis-
ease who did not receive antibiotic treatment compared with those who did (20% vs. 70%,
p = 0.002). In accordance with the disease type, patients withM. kansasii lung disease who
received antibiotic treatment had significantly higher proportion of cavitary lesions on chest
radiographs and HRCT scans compared with patients who did not receive antibiotic treatment
(p = 0.001 on chest radiographs and p< 0.001 on HRCT scans).
Management and Treatment Outcomes in Patients WithM. kansasii
Lung Disease Who Received Antibiotic Treatment
Among the 41 patients who received antibiotic treatment, 16 (39%) initiated anti-tuberculosis
treatment for presumed pulmonary tuberculosis until the definitive identification ofM. kansa-
sii. Regarding treatment regimens forM. kansasii lung disease, 29 (71%) patients received
isoniazid, rifampin, and ethambutol, whereas 12 (29%) were treated with macrolide (azithro-
mycin or clarithromycin), rifampin, and ethambutol (Table 3). The MIC of rifampin and
Fig 1. Diverse patterns in images ofM. kansasii lung disease. (A) A 64-year-old man withM. kansasii lung disease. A coronal thin-section (2.5-mm
thickness) CT scan shows a thick-walled cavitary lesion (arrow) with consolidation in the left upper lobe. Severe pulmonary emphysema is also observed. (B)
A 66-year-old woman withM. kansasii lung disease. A transaxial thin-section (2.5-mm thickness) CT scan obtained at the basal trunk level shows
bronchiectasis (arrows) and multiple branching centrilobular nodules, the so-called tree-in-bud pattern (arrowheads), in both lungs. (C) A-77-year-old man
withM. kansasii lung disease. A transaxial (5-mm thickness) CT scan obtained at the level of the left main bronchus shows two nodules in the left lung
(arrows). Lung biopsy revealed chronic granuloma;M. kansasiiwas isolated from the bronchial washing fluid.
doi:10.1371/journal.pone.0139621.g001
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clarithromycin via the broth microdilution method was available for 23 (56%) of the 41
patients who received treatment and 5 out of 23 patients had resistance to rifampicin.
All patients who completed theM. kansasii treatment course achieved symptomatic and
radiographic improvement and negative microbiologic conversion. Relapse occurred in one
patient after 5 months of following a successful 18-month treatment course of isoniazid, rifam-
pin and ethambutol. This relapse was successfully treated with clarithromycin, rifampin and
ethambutol for 12 months. Treatment ofM. kansasii lung disease was discontinued in three
(7%) patients due to dyspepsia, urticarial, and poor adherence. All patients who received anti-
biotic treatment forM. kansasii disease had negative microbiologic conversion after a median
time of 2.0 months (IQR, 1.0–3.0 months). The median total treatment duration in 41 patients
was 15.0 months (IQR, 7.0–18.0 months) and the median follow-up duration after completion
of intended treatment in 24 patients was 13.7 months (IQR 2.7–45.2 months).
Patients WhoWere Not DiagnosedWithM. kansasii Lung Disease
As shown in Table 4, among 50 patients who did not meet the 2007 ATS/IDSA criteria forM.
kansasii lung disease, 27 (54%) already had another pulmonary disease, including other NTM
lung disease due to MAC (n = 14),Mycobacterium abscessus complex (n = 1), or mixed infec-
tion with MAC andM. abscessus (n = 2) and pulmonary tuberculosis (n = 10). These 27
patients were followed for a median of 22.1 months (IQR, 10.6–27.7months) and a median 6.0
(IQR, 2.0–9.0) sputum cultures were obtained in follow-up period. The remaining 23 (46%)
Table 2. Clinical manifestations of 54 patients diagnosed withM. kansasii lung disease.
Total (n = 54, 100%) Antibiotic treatment (n = 41, 76%) Observation (n = 13, 24%) P value
Males, n 39 (72) 31 (76) 8 (62) 0.478
Age, years 62 (45–66) 59 (45–66) 64 (53–74) 0.252
Body mass index, kg/m2 20.7 (18.7–22.8) 20.5 (18.7–22.4) 20.9 (18.3–25.4) 0.463
Symptom
Cough 35 (65) 28 (68) 7 (54) 0.342
Sputum 40 (74) 31 (76) 9 (70) 0.722
Hemoptysis 11 (20) 10 (24) 1 (8) 0.261
Dyspnea 18 (33) 16 (39) 2 (15) 0.179
Positive AFB smear 36 (67) 30 (73) 6 (46) 0.096
Type of disease
Fibrocavitary 24 (44) 23 (56) 1 (8) 0.002
Nodular- bronchiectatic 17 (32) 8 (20) 9 (70) 0.002
Unclassiﬁable 13 (24) 10 (24) 3 (23) 1.000
Chest radiograph ﬁndings
Cavity 25 (46) 24 (59) 1 (8) 0.001
Bronchiectasis 23 (43) 15 (37) 8 (62) 0.113
Nodules or consolidation 30 (56) 23 (56) 7 (54) 0.887
HRCT ﬁndings
Cavity 27 (50) 26 (63) 1 (8) <0.001
Bronchiectasis 32 (59) 22 (54) 10 (77) 0.137
Centrilobular nodules 38 (70) 27 (66) 11 (85) 0.301
Consolidation 26 (48) 21 (51) 5 (39) 0.422
All data are presented as numbers (%) or as medians and interquartile ranges
AFB = acid-fast bacilli; HRCT = high-resolution computed tomography.
doi:10.1371/journal.pone.0139621.t002
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patients had only a single sputum isolate out of two or more respiratory specimens taken dur-
ing the follow-up period; this result was insufficient to meet the microbiological criteria for
Table 3. Management and treatment outcomes of the 41 patients who received antibiotic treatment
forM. kansasii lung disease.
No. of patients (%) or median (IQR)
Initially presumed as pulmonary tuberculosis 16 (39)
Treatment regimen for M. kansasii disease
INH / RIF / EMB 29 (71)
Macrolide (AZT or CLR) / RIF / EMB 12 (29)
RIF susceptible, n/total n* 20 / 23 (87)
CLR susceptible, n/total n* 23 / 23 (100)
Treatment outcomes
Completed treatment 24 (59)
Ongoing treatment 8 (20)
Lost or transferred during treatment 6 (15)
Discontinued treatment** 3 (7)
Death during treatment due to disease 0 (0)
Time from diagnosis to initiation of treatment, months 1.7 (0.3–3.8)
Time to sputum negative conversion, months 2.0 (1.0–3.0)
Treatment duration, months 15.0 (7.0–18.0)
Follow-up duration after diagnosis, months 24.1 (12.4–37.6)
Follow-up duration after treatment completion, months† 13.7 (2.7–45.2)
Data are presented as numbers (%) or as medians and interquartile ranges.
IQR = interquartile ranges; INH = isoniazid; RIF = rifampin; EMB = ethambutol; AZT = azithromycin;
CLR = clarithromycin.
*The rifampin susceptibility test was performed in 23 patients.
**Two patients discontinued medications due to side effects like dyspepsia, anorexia, and urticarial;
another patient self-discontinued due to improved respiratory symptoms.
†Calculated from the data of 24 patients who completed scheduled treatment.
doi:10.1371/journal.pone.0139621.t003
Table 4. Reasons why 50 patients did not meet the 2007 ATS/IDSA diagnostic criteria forM. kansasii
disease.
Reason No. of patients (%)
Clinical criteria
Excluded due to other disease 27 (54)
Mycobacterium avium complex 14
Mycobacterium abscessus complex 1
Mixed NTM infection* 2
Pulmonary tuberculosis** 10
Microbiologic criteria
Culture-positive from only a single sputum sample† 23 (46)
*Two patients were diagnosed with mixed infection (M. avium complex and M. abscessus).
**Pulmonary tuberculosis was demonstrated by the presence of an M. tuberculosis culture isolate or by
polymerase chain reaction.
†Of these patients, 18 (78%) underwent follow-up without antibiotic treatment for a median duration of 12.1
months (interquartile range 4.4–32.0 months). None of these patients developed M. kansasii lung disease.
doi:10.1371/journal.pone.0139621.t004
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NTM lung disease. Although these patients did not fulfill the 2007 ATS/IDSA diagnostic crite-
ria, 5 out of the 23 (22%) were treated with a presumed diagnosis of pulmonary tuberculosis or
M. kansasii lung disease. The remaining 18 of 23 (78%) patients were observed without antibi-
otic treatment for a median 12.1 months (IQR, 4.4–32.0 months) follow-up period. A median
of 4.0 (IQR 2.8–10.3) sputum cultures were performed and none of these patients developed
M. kansasii lung disease.
Discussion
This study evaluated the clinical relevance and disease characteristics in 104 patients from whom
M. kansasii respiratory isolates were obtained. We found that 52% of all patients withM. kansa-
sii-positive respiratory cultures were ultimately diagnosed withM. kansasii lung disease; 76% of
these patients received antibiotic treatment and had a favorable outcome. Moreover,M. kansasii
lung disease exhibited diverse radiographic findings, including the nodular bronchiectatic form.
Finally, we found that the isolation ofM. kansasii from patients with tuberculosis or another
NTM disease or a single sputum isolate was not associated with the development ofM. kansasii
lung disease during the follow-up period in patients who did not satisfy the diagnostic criteria.
Our study included more than 100 patients, none of whom had HIV. Moreover, 52% of all
patients from whom anM. kansasii respiratory isolate was obtained had clinically relevant dis-
ease. This finding is consistent with recent epidemiologic studies in Israel, Croatia and the
Netherlands using the 2007 ATS/IDSA diagnostic criteria [25–27]. However, the clinical signif-
icance ofM. kansasii respiratory isolates has been shown to vary from 17% to 88% (Table 5).
Table 5. Clinical relevance ofM. kansasii respiratory isolates in previous reports.
Author, year, reference Country Study period Clinical relevance*
Fogan, 1969 [34] Oklahoma, USA 1966–1968 50% (18/36)
Jenkins, 1981 [9] Wales, UK 1952–1978 84% (154/184)
O’Brien, 1987 [10] USA 1981–1983 75% (762/1016)
Pang, 1991 [35] Australia 1962–1987 48% (39/81)
Debrunner, 1992 [32] Switzerland 1983–1988 26% (9/35)
Bloch, 1998 [11] California, USA 1992–1996 88% (236/270)**
Corbett, 1999 [31] South Africa 1996–1997 41% (23/56)†
Koh, 2006 [16] South Korea 2002–2003 50% (7/14)
Bodle, 2008 [28] New York City, USA 2000–2003 70% (7/10)
Van Ingen, 2009 [29] Netherlands 1999–2005 71% (12/17)
Thomson, 2010 [36] Australia 2005 53% (10/19)
Winthrop, 2010 [30] Oregon, USA 2005–2006 38% (3/8)
Simons, 2011 [12] Asia 1971–2007 17% (34/198)
Davies, 2012 [33] UK 2000–2007 73% (40/55)
Braun, 2012 [25] Israel 2004–2010 50% (7/14)
Jankovic, 2013 [26] Croatia 2006–2010 50% (5/10)
Chien, 2014 [37] Taiwan 2000–2012 44% (234/526)
Gommans, 2015 [27] Netherlands 2001–2011 53% (10/19)
Current study South Korea 2003–2014 52% (54/104)
USA = United States of America, UK = United Kingdom.
*Proportion of patients judged to have M. kansasii lung disease out of all patients from whom M. kansasii had been isolated.
**187 (69%) were HIV-positive.
†40 (34%) were HIV-positive.
doi:10.1371/journal.pone.0139621.t005
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This wide range of clinical significance might be explained by small study sizes [28–30], the
inclusion of many patients with pneumoconiosis [9] or HIV [11, 31], or the use of previous
diagnostic criteria [10, 12, 32]. One epidemiologic study in the UK [33] excluded patients with
a single sputum isolate, leading to a relatively high estimation of the clinical relevance ofM.
kansasii respiratory cultures.
In contrast to previous findings regarding the virulence and clinical significance of a single
M. kansasii isolate, we found that 18 patients with a single sputum isolate did not developM.
kansasii lung disease during the follow-up period. This result supports the 2007 ATS/IDSA
diagnostic criteria for infection withM. kansasii, MAC, andM. abscessus complex, according
to which a single positive sputum culture is regarded as indeterminate for the diagnosis of
NTM lung disease [5].
Patients withM. kansasii lung disease typically present with upper-lobe fibronodular infil-
trates with cavitation on chest radiographs [7]. In our study, the nodular bronchiectatic and
unclassifiable forms were also commonly observed in patients withM. kansasii lung disease,
especially those who did not receive antibiotic treatment. This finding is consistent with a
recent study [27] in which, various radiographic findings ofM. kansasii lung disease were
reported. Our findings imply that patients withM. kansasii lung disease can also exhibit the
nodular bronchiectatic form, similar to other patients with NTM lung disease.
Regarding treatment forM. kansasii lung disease, we found that 76% of all patients withM.
kansasii disease received antibiotic treatment, while the remaining 24% presented an indolent
course and did not require antibiotic treatment. Similar to previous reports of good prognoses
[5, 7, 38], all patients who completed treatment showed a favorable response. Moreover, no
treatment failure occurred, despite the presence of rifampin-resistant isolates in 3 out of the 23
patients. Regarding treatment regimen, 29% of all patients who underwent antibiotic treatment
forM. kansasii lung disease received a macrolide-containing regimen with rifampin. The cur-
rent ATS/IDSA recommendation for treatingM. kansasii lung disease is an 18-month regimen
consisting of daily isoniazid, rifampin, and ethambutol therapy. However, untreatedM. kansa-
sii strains are easily inhibited in vitro by clarithromycin at lower concentrations than those
required for MAC treatment [39], a result that is readily achievable with the standard therapeu-
tic doses. In addition, a preliminary study showed that the administration of clarithromycin,
rifampin, and ethambutol for the treatment ofM. kansasii lung disease resulted in favorable
treatment outcomes in 18 patients [40]. At our institution, the treatment protocol was changed
from including isoniazid to including macrolide antibiotics in January 2013 after discussion
regarding treatment ofM. kansasii lung disease. Although our sample size was small and some
patients are still treatment, our study yielded important preliminary observations regarding the
potential of regimens containing macrolide, rifampin, and ethambutol for treatingM. kansasii
lung disease. Further studies with larger sample sizes are needed to confirm this finding.
Our study did have several limitations. First, this retrospective study was conducted at a sin-
gle referral institution and thus we were unable to calculate the population-based prevalence.
Second, the clinical significance ofM. kansasii positivity in patients withM. kansasii isolates
who were administered antibiotics (including rifampin) due to accompanying tuberculosis or
another NTM disease remains unclear. In addition, as genotyping was not performed in one
recurred case, relapse could not be distinguished from re-infection. Finally, althoughM. kansa-
sii is a heterogeneous species with several distinct subtypes [41], clinical significance was not
evaluated according toM. kansasii subtype.
In conclusion, about half of all patients from whomM. kansasii was isolated from the respi-
ratory specimen presented clinically significant lung disease with diverse radiographic findings.
Similar to other NTM lung disease, patients withM. kansasii lung disease can exhibit the nodu-
lar bronchiectatic form, especially with an indolent clinical course. The clinical significance of
Clinical Significance ofM. kansasiiRespiratory Isolates
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a singleM. kansasii isolate was not conclusive, suggesting strict adherence to the recommended
diagnostic criteria.
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